Möchten Sie immer auf dem neuesten Stand bleiben?

EAACI Congress 2026 concluded in Istanbul, welcoming 7,429 delegates from 110 countries and marking the start of Mohamed Shamji's Presidency.

ALK announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EURneffy® 1 mg, the first and only needle-free adrenaline treatment for...

Over half (54%) of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed—and nearly 40% do not carry one regularly (n=1,238 ).1HCP survey data...

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company...

EAACI, together with AEPNAA, SEAIC, and SEICAP, has called for urgent action to improve the safety of children at risk of anaphylaxis in schools.

Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European...

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Peanut Allergy Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035" has been added to ResearchAndMarkets.com's...

ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis.

Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control